(+)-VINCRISTINE
Digestive System Diseases
PfizerSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Digestive System Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
pf-08634404 Pfizer | Phase 3 | B |
Sorafenib Abbott | Phase 3 | B |
Linifanib Abbott | Phase 3 | B |
htd1801 HighTide Biopharma Pty Ltd | Phase 2 | B |
Eloxatin Zhejiang University | Phase 2 | B |
View all 15 →
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →